Intravenous Iron Drugs Market Innovations and Differentiation in the Competitive Landscape

Revenue, 2025

USD 3.65 Billion

Forecast, 2035

USD 8.74 Billion

CAGR, 2026-2035

9.14%

Report Coverage

Global

Intravenous Iron Drugs Market Trends for 2026

The global intravenous iron drugs market size was estimated at USD 3.65 billion in 2025 and is predicted to increase from USD 3.98 billion in 2026 to approximately USD 8.74 billion by 2035, expanding at a CAGR of 9.14% from 2026 to 2035.

The intravenous iron drugs market is growing as intravenous iron replacement product applied to manage iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).

Key Takeaways

• Intravenous iron drugs sector pushed the market to USD 3.98 billion by 2026.
• Long-term projections show USD 8.74 billion valuation by 2035.
• Growth is expected at a steady CAGR of 9.14% in between 2026 to 2035.
• North America dominated the intravenous iron drugs market in 2025, with approximately 50.0% market share.
• Asia Pacific is expected to grow at the fastest CAGR of approximately 9.4% in the market during the forecast period.
• By product type, the ferric carboxymaltose segment dominated the market in 2025 with approximately 48% share.
• By product type, the iron isomaltoside segment is expected to grow at the fastest CAGR of approximately 10.1% in the market during the forecast period.
• By application, the chronic kidney disease segment dominated with approximately 35% share in 2025.
• By application, the oncology/cancer anemia segment is expected to grow at the fastest CAGR of approximately 9.8% in the market during the forecast period.
• By end user, the hospitals segment dominated the market in 2025 with approximately 58.5% share.
• By end user, the home infusion/telehealth segment is expected to grow at the fastest CAGR of approximately 11.0% in the market during the forecast period.

Market Overview: What are Intravenous Iron Drugs?

The intravenous iron drugs market is growing because IV iron has become crucial for treating iron deficiency and anemia. These medications are used in various clinical situations, such as chronic kidney disease, cancer-related anemia, and gastrointestinal bleeding. They offer faster treatment compared to tablets or dietary changes. Intravenous iron therapy allows for quick replenishment of iron stores and resolution of anemia, with fewer gastrointestinal side effects. The use of IV iron as a first-line treatment in children with chronic conditions has also increased. IV iron helps quickly correct anemia and reduces the need for ESAs compared to oral iron, without evidence of renal toxicity.

How is AI Governing the Intravenous Iron Drugs Market?

Integration of AI-driven technology in intravenous iron drugs drives the growth of the market, driven by AI-based diagnostics and smart infusion tools that enhance dosing and treatment schedules. An AI-based system analyzes a patient's response to prior infusion management and adjusts dosages and drug blends accordingly. Integrating clinical laboratory medicine with an AI-based system enables the extraction and analysis of extensive feature data from clinical tests. AI in medicine includes its varied applications in areas like medical image analysis, drug discovery, and targeted treatment planning.

Future Outlook & Trends in the Intravenous Iron Drugs Market

Decentralized and Hybrid Models:

Novel iron formulations allow for a total dose infusion (TDI) in 15 to 60 min, obviating multiple unnecessary visits for the same clinical advantages without added toxicity.

 Increased adoption of ambulatory and outpatient infusion centres:

Trends in ambulatory infusion centers are the incessant development of infusion tools. Modern infusion pumps, which are more accurate and consumer-friendly, are enabling AICs to administer treatments more efficiently.

Technological Innovations: 

Intravenous infusions of iron have advanced from a poorly active and dangerous intervention to a safe keystone in the treatment of iron deficiency.

Quick Facts Table

Segmentation Analysis

By Product Type Insights

Which Product Type Led the Intravenous Iron Drugs Market in 2025?

In 2025, the ferric carboxymaltose segment held the dominant market share with approximately 48% share in 2025, due to ferric carboxymaltose being an iron replacement therapy applied to treat iron deficiency anemia in offspring and adults with intolerance or inadequate clinical response to oral iron, and in adult patients who have non-dialysis dependent chronic kidney disease.  Intravenous ferric carboxymaltose is a stable multifaceted product with the advantage of being non-dextran-containing and having a low immunogenic strength.

Iron Isomaltoside

Whereas the iron isomaltoside segment is estimated to be the fastest-growing with a CAGR of approximately 10.1% in the market, as iron isomaltoside is a potential treatment choice for iron deficiency in patients experiencing elective surgery.  Its applications are in IV formulations for pets, livestock, and horses, especially during periods of stress, disease, or surgery. Iron isomaltoside’s capability to deliver iron proficiently and safely has expanded its use in various industries, from pharmaceuticals to nutraceuticals and veterinary care, making it a multipurpose and valuable compound.

By Application Insights

Why did the Chronic Kidney Disease Segment Dominate the Market in 2025?

The chronic kidney disease segment was dominant in the intravenous iron drugs market, with approximately 35% share in 2025, as CKD-ND patients have suggested potential advantages of initiating IV iron therapy before dialysis onset. IV iron is effective for patients in later stages of CKD, particularly if they are getting haemodialysis treatments. Intravenous iron supplementation has become a backbone of therapy in the management of CKD-related anemia.

Oncology/Cancer Anemia

Whereas the oncology/cancer anemia segment is estimated to be the fastest-growing, with a CAGR of approximately 9.8% in the market, as IV iron raises hemoglobin concentration and decreases transfusion rates during different cancer treatment administrations. IV iron is administered safely through the cancer treatment pathway from the main surgery to the palliative setting. IV iron enhances measures of hematopoiesis and iron metabolism in patients with cancer and anemia who are treated with chemotherapy.

By End-User Insights

Why did the End-User Segment Dominate the Market in 2025?

The hospitals segment was dominant in the intravenous iron drugs market with approximately 58.5% share in 2025, as intravenous infusions of iron have progressed from a poorly effective and dangerous involvement to a safe and significant role in the treatment of iron deficiency. Intravenous iron provides advantages over oral iron for the treatment of iron deficiency anemia in a broad range of disease states. IV iron quickly raises iron and hemoglobin levels in the bloodstream and replenishes body iron stores much more rapidly than oral supplements.

Home Infusion/Telehealth

Whereas the home infusion/telehealth segment is estimated to be the fastest-growing with a CAGR of approximately 11.0% in the market, as Home infusion care can provide safe, clinically effective care, improve patients' quality of life, and lower healthcare expenses. Home infusion therapy, from ease and convenience to concentrated hospital visits. Home infusions are often more costly than lengthy hospital stays or frequent outpatient solutions visits.

Regional Insights

How did North America dominate the Market in 2025?

In 2025, North America dominated the intravenous iron drugs market with approximately 50% share, as healthcare and private insurers are investigating bundled payment models. Intravenous (IV) iron therapy is a broadly accepted, safe, and effective treatment for iron deficiency anemia. High prevalence of iron deficiency anemia in patients with chronic kidney disease. Increasing government approval, such as FDA approval of Injectafer, a non–dextran-containing iron therapy, provides a new IV treatment choice for patients with iron-deficiency anemia, which drives the growth of the market.

For Instance,

• In January 2025, Akeso, Inc. is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", offering an in-depth analysis of 20 significant drugs poised to define the trajectory of the worldwide pharmaceutical sector and transform disease treatment paradigms in 2026 and beyond.

U.S. Market Trends

In the U.S., rapidly growing aging populations and associated demographic shifts, growing disease burdens, and widening gaps in equity demand speed up action. Improved government flexibility for combination therapies, enhancing treatment results in cancer and genetic diseases. The FDA prioritization of expedited approvals and expedited pathways is warranted for medicines with potentially life-saving characteristics.

Asia Pacific: Presence of Advanced Healthcare Infrastructures

Asia Pacific is expected to see rapid growth of approximately 9.4% in the intravenous iron drugs market, driven by this region accounting for more than 85 % of the absolute anemia load in high-risk groups, and India is the worst hit, with a growing demand for intravenous iron drugs. The APAC healthcare sector has high growth, and the presence of major organizations that drive innovation. Much of the healthcare in Asia and the Pacific, particularly in urban areas, is provided by the private sector, which drives the growth of the market.

India Market Trends

India's anaemia disaster is being exacerbated by a lack of awareness, poor nutrition, and increasing levels of air pollution. India’s anaemia rate is the highest in the global with India’s National Family Health Survey indicating more than 50% of pregnant women were affected by anaemia. Increasing government support, such as India’s Anaemia Mukt Bharat-Intensified National Iron Plus Initiative, aims to lower the prevalence of anaemia in reproductive-age women.

Prevalence of anaemia in Aspirational and non-aspirational Districts in NFHS-4 and NFHS-5

Value Chain Analysis

R&D:

• R&D processes in intravenous iron drugs involve preclinical formulation advancement and characterization, preclinical safety and efficacy testing, clinical trial development, and many other activities.
• Key Players: CSL Vifor and Daiichi Sankyo Company, Ltd.

Manufacturing Processes:

• Major manufacturing processes involved in clinical trial drug sourcing are highly controlled, multi-stage, sterile, and complex chemical processes.
• Key Players: Pharmacosmos A/S, and Fresenius Kabi AG

Patient Services:

• Key services involve a comprehensive, multi-stage process designed to safely and efficiently increase hemoglobin and iron levels when oral supplements are ineffective or unsuitable.
• Key Players: Sanofi, Pharmacosmos A/S, and Fresenius Kabi AG

Latest Updates of Key Players in the Intravenous Iron Drugs Market

SWOT Analysis

Strengths

• Managing anemia is with intravenous iron, or an iron infusion, which is delivered in a vein via a needle to increase the levels of iron and hemoglobin in iron deficiency patient.
• As compared to oral iron supplements, iron infusions deliver iron directly into the bloodstream. This results in a much faster and more significant increase in iron levels, which is significant for tackling severe anaemia.

Weakness

• Intravenous iron drugs cause faintness, dizziness, or light-headedness when getting up suddenly from a lying or sedentary position.

Opportunities

• FDI is approved for a 1000 mg infusion or doses up to 20 mg/kg, not to exceed 1500 mg. It should be diluted in 100 mL of normal saline and infused with similar precautions as the various formulations.
• Intravenous single-dose ferric derisomaltose is a well-tolerated and efficient choice for iron deficiency anemia in pregnancy.

Threat

• Intravenous iron causes complex hypersensitivity reactions, which can be lethal. The challenges of sensitivity is rised in patients with known allergies, immune or inflammatory situations.

Recent Developments in the Intravenous Iron Drugs Market

• In November 2025, Viatris (VTRS) announced the FDA had approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to manage iron deficiency anemia in adult and pediatric patients with chronic kidney disease.
• In September 2025, Sandoz, the worldwide leader in cost-effective medicines, announced the US launch of its generic iron sucrose injection following recent approval by the US Food and Drug Administration (FDA).
• In August 2025, Viatris Inc., a global healthcare company, announced the U.S. Food and Drug Administration (FDA) had approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients with chronic kidney disease.

Segments Covered in the Report

By Product Type

• Ferric Carboxymaltose
• Iron Sucrose
• Iron Isomaltoside
• Iron Dextran & Others

By Application

• Chronic Kidney Disease
• Oncology
• Gastroenterology
• Gynecology & Others

By End-User

• Hospitals
• Homecare/Ambulatory
• Dialysis Centers

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA